Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts

Clinical Cancer Research

Volumn 5, Issue 11, 1999, Pages 3617-3631

  Thompson, Joyce ^a   George, E Olusegun ^a   Poquette, Catherine A ^a   Cheshire, Pamela J ^a   Richmond, Lois B ^a   De Graaf, Siebold S N ^b   Ma, Margaret ^a   Stewart, Clinton F ^a   Houghton, Peter J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

TOPOTECAN; VINCRISTINE;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; CANCER REGRESSION; CHILDHOOD CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISPOSITION; DRUG POTENTIATION; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MAXIMUM PERMISSIBLE DOSE; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SOLID TUMOR; THROMBOCYTOPENIA; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CEREBELLAR NEOPLASMS; CHILD; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MEDULLOBLASTOMA; MICE; MICE, INBRED CBA; NEUROBLASTOMA; RHABDOMYOSARCOMA; THYMECTOMY; TOPOTECAN; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; VINCRISTINE; WHOLE-BODY IRRADIATION;

EID: 0032758266     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Houghton, P. J., Cheshire, P. J., Myers, L., Stewart, C. F., Synold, T. W., and Houghton, J. A. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother. Pharmacol., 31: 229-239, 1992.
2. Friedman, H. S., Houghton, P. J., Schold, S. C., Keir, S., and Bigner, D. D. Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother. Pharmacol., 34: 171-174, 1994.
3. Houghton, P. J., Cheshire, P. J., Hallman, J. D., II, Lutz, L., Friedman, H. S., Danks, M. K., and Houghton, J. A. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol., 36: 393-403, 1995.
4. Thompson, J., Stewart, C. F., and Houghton, P. J. Animal models for studying the action of topoisomerase I targeted drugs. Biochim. Biophys. Acta, 1400: 301-319, 1998.
5. Emerson, D. L. Besterman, J. M., Brown, H. R., Evans, M. G., Leitner, P. P., Luzzio, M. J., Shaffer, J. E., Sternbach, D. D., Uehling, D., and Vuong, A. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues. Cancer Res., 55: 603-609, 1995.
6. D'Arpa, P., Beardmore, C., and Lui, L. F. Involvement of nucleic acid synthesis in killing mechanisms of topoisomerase poisons. Cancer Res., 50: 6919-6924, 1990.
7. Kaufmann, S. H. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res., 57: 1129-1136, 1991.
8. Bertrand, R., O'Connor, P. M., Kerrigan, D., and Pommier, Y. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur. J. Cancer. 28A: 743-748, 1992.
9. Chou, T. C., Motzer, R. J., Tong, Y., and Bosl, G. J. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design [see comments]. J. Natl. Cancer Inst., 86: 1517-1524, 1994.
10. Kaufmann, S. H., Peereboom, D., Buckwalter, C. A., Svingen, P. A., Grochow, L. B., Donehower, R. C., and Rowinsky, E. K. Cytotoxic effects of topotecan combined with various anticancer agents inhuman cancer cell lines [see comments]. J. Natl. Cancer Inst., 88: 734-741, 1996.
11. Janss, A. J., Craan, A., Spilsky, A., Levow, C., Yao, Y., and Phillips, P. C. Synergistic cytotoxic effects of camptothecin and topotecan with alkylating agents are drug-specific and dose-dependent in human brain tumor cell lines. Proc. Am. Assoc. Cancer Res., 37: 294, 1996.
12. Waud, W. R., Rubenstein, L. V., Kalyandrug, S., Plowman, J., and Alley, M. C. In vivo combination chemotherapy evaluations of topotecan with cisplatin and temozolomide. Proc. Am. Assoc. Cancer Res., 37: 292, 1996.
13. Houghton, J. A., Cheshire, P. J., Hallman, J. D., Lutz, L., Luo, X., Li, Y., and Houghton, P. J. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma. Clin. Cancer Res., 2: 107-118, 1996.
14. Whitacre, C. M., Zborowska, E., Gordon, N. H., Mackay, W., and Berger, N. A. Topotecan increases topoisomerase IIα levels and sensitivity to treatment with etoposide in schedule-dependent process. Cancer Res., 57: 1425-1428, 1997.
15. Kim, R., Hirabayashi, N., Nishiyama, M., Jinushi, K., Toge, T., and Okada, K. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int. J. Cancer, 50: 760-766, 1992.
16. Castano, I. B., Brzoska, P. M., Sadoff, B. U., Chen, H., and Christman, M. F. Mitotic chromosome condensation in the rDNA requires TRF4 and DNA topoisomerase I in Saccharomyces cerevisiae. Genes Dev., 10: 2564-2576, 1996.
17. Houghton, J. A., Cook, R. L., Lutz, P. J., and Houghton, P. J. Childhood rhabdomyosarcoma xenografts: response to DNA interacting agents and agents used in current clinical therapy. Eur. J. Cancer Clin. Oncol., 20: 955-960, 1984.
18. Houghton, J. A., Williams, L. G., Dodge, R. K., George, S. L., Hazelton, B. J., and Houghton, P. J. Relationship between binding affinity, retention and sensitivity of human rhabdomyosarcoma xenografts to Vinca alkaloids. Biochem. Pharmacol., 36: 81-88, 1987.
19. Pratt, C. B., Stewart, C., Santana, V. M., Bowman, L., Furman, W., Ochs, J., Marina, N., Kuttesch, J. F., Heideman, R., Sandlund, J. T., et al. Phase I study of topotecan for pediatric patients with malignant solid tumors. J. Clin. Oncol., 12: 539-543, 1994.
20. Kretchmar, C., Kletzel, M., Murray, K., Joshi, V., Smith, E., Pao, P. V., and Castlebury, R. Upfront Phase II therapy with Taxol (Tx1) and topotecan (Topo) in untreated children (>365 days) with disseminated (INSS stage 4) neuroblastoma (NB). A Pediatric Oncology Group (POG) Study. Med. Pediatr. Oncol., 25: 243A, 1995.
21. Vietti, T., Crist, W., Ruby, E., Raney, B., Ruyman, F., Link, M., Grier, H., and Maurer, H. Topotecan window in patients with rhabdomyosarcoma (RMS): an IRSG study. Proc. Am. Assoc. Clin. Oncol., 16: 510A, abstract #1837, 1997.
22. Zamboni, W. C., Stewart, C. F., Thompson, J., Santana, V., Cheshire, P. J., Richmond, L. B., Liu, X., Houghton, J. A., and Houghton, P. J. The Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J. Natl. Cancer Inst., 90: 505-511, 1998.
23. Thompson, J., Zamboni, W. C., Cheshire, P. J., Lutz, L., Luo, X., Li, Y., Houghton, J. A., Stewart, C. F., and Houghton, P. J. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin. Cancer Res., 3: 423-431, 1997.
24. Houghton, J. A., Houghton, P. J., Hazelton, B. J., and Douglass, E. C. In situ selection of a human rhabdomyosarcoma resistant to vincristine with altered β-tubulins. Cancer Res., 45: 2706-2712, 1985.
25. Beijnen, J. H., Smith, B. R., Keijer, W. J., Van Gijn, R., Huinink, W. W., Vlasveld, L. T., Rodenhuis, S., and Underberg, W. J. M. High-performance liquid Chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma. J. Pharm. Biomed. Anal., 8: 789-794, 1990.
26. Zamboni, W. C., Stewart, C. F., Thompson, J., Santana, V. M., Cheshire, P. J., Richmond, L. B., Xiaolong, L., Poquette, C., Houghton, J. A., and Houghton, P. J. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J. Natl. Cancer Inst., 90: 505-511, 1998.
27. Crom, W. R., de Graaf, S. S. N., Synold, T., Uges, D. R. A., Bloemhof, H., Rivera, G., Christensen, M. L., Mahmoud, H., and Evans, W. E. Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J. Pediatr., 125: 642-649, 1994.
28. de Graaf, S. S. N., Bloemhof, H., Vendrig, D. E. M. M., and Uges, D. R. A. Vincristine disposition in children with acute lymphoblastic leukemia. Med. Pediat. Oncol., 24: 235-240, 1995.
29. D'Argenio, D. Z., and Schumitzky, A. ADAPT II User's Guide. University of Southern California. Los Angeles, CA: Biomedical Simulations Resource, 1990.
30. Gibaldi, M., and Perrier, D. Pharrnacokinetics. New York: Marcel Dekker, 1982.
31. Yeh, K. C., and Kwan, K. C. A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation. J. Pharmacokinet. Biopharm., 6: 79-98, 1978.
32. Giltinan, D. M., Capizzi, T. P., and Malani, H. Diagnostic tests for similar action of two compounds. Appl. Statistics, 37: 39-50, 1988.
33. Hochberg, Y., and Tamhane, A. Multiple comparison procedures, pp. 94-96. New York: John Wiley & Sons, 1987.
34. Tubergen, D. G., Stewart, C. F., Pratt, C. B., Zamboni, W. C., Winick, N., Santana, V. M., Dryer, Z. A., Kurtzberg, J., Bell, B., Grier, H., et al. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: A Pediatric Oncology Group study. J. Pediatr. Hematol. Oncol., 18: 352-361, 1996.